incyte Eczema / Sleep Disturbacne (902)
Participation Information
Volunteers needed for an 8 week long treatment period (with participation lasting up to 18 weeks total). This clinical trial is for a topical cream that is FDA approved for Atopic Dermatitis called Ruxolitinib cream 1.5%. Stipend available up to $375.00 (5 x $75 / visit) to those who qualify and participate.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18 years of age or older
2.) Have between 3 and 20% body surface area with eczema (atopic dermatitis)
3.) Sleep interruption due to itch from eczema (atopic dermatitis)
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Works nighttime shifts
2.) Itch due to chronic liver or kidney disease
3.) Hepatitis B or C infection (current or previous)
ClinicalTrials.gov Identifier: NCT05696392
